U.S. FDA Approves Subcutaneous Induction Regimen for AbbVie's SKYRIZI® (risankizumab-rzaa) for Adults With Moderately to Severely Active Crohn's Disease

Now with a new route of induction administration, subcutaneous SKYRIZI supports early symptomatic and endoscopic control with an on-body injector (OBI) device throughout the course of treatment In the pivotal Phase 3 AFFIRM study, subcutaneous (SC) SKYRIZI® achieved superior clinical remissioni and endoscopic responseii at week 12 compared with placebo in patients with Crohn's disease; results were particularly strong in patients without prior advanced therapy failureiii The safety profile of subcutaneous induction was generally consistent with the established SKYRIZI profile in Crohn's disease, with no new safety risks identified FDA also approved an update to the U.S. Prescribing Information warning and precautions across all indications to allow healthcare providers to use clinical judgment when determining whether tuberculosis (TB) testing is needed NORTH CHICAGO, Ill., Oct. 23, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced the U.S. Food and Drug Administration has approved a subcutaneous (SC) induction regimen for SKYRIZI® (risankizumab-rzaa) for adults with moderately to severely active Crohn's disease (CD)iv.

PRNewsWire • a day ago

AbbVie (ABBV) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

AbbVie (ABBV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Investment Research • Oct 23, 2026

Forget Chasing 7% Yields: These 5 Dividend Stocks Offer Something Different

Treasury yields have turned dividend investing into a minefield, but five mega-caps have quietly raised their payouts through every rate spike, recession, and patent cliff of the past four decades.

24/7 Wall Street • a day ago

AbbVie's Dividend Survived Humira's Patent Cliff. Will Merck and Amgen's?

When a drugmaker's top product loses patent protection, the dividend usually takes the hit.

24/7 Wall Street • a day ago

The Dividend Aristocrats Ranked By Quality Scores (October 2026)

I rank all 69 S&P 500 Dividend Aristocrats by my 9F Quality Scores, segmenting them into undervalued, fairly valued, and overvalued groups. My consensus fair value estimates, blending up to 40 data points per stock, highlight 12 undervalued and 18 fairly valued Aristocrats, with 39 currently overvalued. Investment candidates vary by style: ADP, BRO, and NDSN for growth; NEE for total return; PEP and O for income; CAT and GWW for past performance.

Seeking Alpha • Oct 23, 2026

BMY vs. ABBV: Which Pharma/Biotech Stock Offers More Upside Potential?

Bristol Myers edges out AbbVie with a cheaper valuation and higher dividend yield, but pipeline execution, legacy drug declines and debt remain key risks.

Zacks Investment Research • Oct 23, 2026

AbbVie's skin disease drug reduces lesions in trial, company eyes weight-loss combination

AbbVie said on Thursday its experimental drug significantly reduced inflammatory lumps and abscesses in patients with a chronic skin disease, meeting the ​main goal of a late-stage study.

Reuters • Oct 22, 2026

Great News for AbbVie Stock Investors

AbbVie posted strong Phase 2a results for a potential successor to Skyrizi in Crohn's disease. The company also has a promising eczema candidate that could cement its position in immunology.

The Motley Fool • Oct 22, 2026

AbbVie Announces Topline Results from the Phase 3 INTREPID Trial Showing Lutikizumab Significantly Improved Signs and Symptoms of Disease in Patients with Hidradenitis Suppurativa

In the Phase 3 INTREPID study, lutikizumab achieved the primary endpoint of Hidradenitis Suppurativa Clinical Response 75 (HiSCR75) at Week 16 compared with placebo1 Lutikizumab met 8 ranked secondary endpoints, including significant improvements in HS-related skin pain at Week 8 and significant reductions in the occurrence of HS flares over the first 16 weeks,1 reflecting outcomes assessed by both patients and physicians Lutikizumab was generally well tolerated, with no new safety concerns identified1 INTREPID provides Phase 3 data supporting the continued investigation of simultaneous inhibition of IL-1α and IL-1β as a potential treatment approach in adults and adolescents with moderate to severe HS1 NORTH CHICAGO, Ill., Oct. 22, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced positive topline results from the Phase 3 INTREPID study evaluating the safety and efficacy of lutikizumab, an investigational dual-variable-domain interleukin (IL) 1α/1β antagonist, in adults and adolescents with moderate to severe hidradenitis suppurativa (HS).

PRNewsWire • Oct 22, 2026

AbbVie (ABBV) Is Considered a Good Investment by Brokers: Is That True?

Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?

Zacks Investment Research • Oct 22, 2026